Pay in 4 interest-free payments of $6.18 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
Article: GHK-Cu vs AHK-Cu: Which Copper Peptide Is More Effective
Patel: Exactly
Add-on to 1-3 oral anti-hyperglycemic agents (metformin, sulfonylurea, or SGLT-2 inhibitor) SURPASS-4 (NCT03730662) was a 104-week open-label trial (52-week primary endpoint) that randomized 2002 adult patients with type 2 diabetes mellitus with increased cardiovascular risk to subcutaneous MOUNJARO 5 mg, MOUNJARO 10 mg, MOUNJARO 15 mg once weekly, or insulin glargine 100 units/mL once daily (1:1:1:3 ratio) on a background of metformin (95%) and/or sulfonylureas (54%) and/or SGLT2 inhibitors (25%)
Daily dosing would risk supratherapeutic accumulation and is not supported by the published pharmacokinetic data
Orders are typically delivered within 37 working days
US$ 22.84
US$ 26.03
US$ 21.47
US$ 29.30
